Vaxinano

Vaxinano is a French biotech SME specializing in the development of prophylactic and therapeutic vaccines against infectious diseases. Our proprietary technology is based on GMP-grade maltodextrin nanoparticles, enabling intranasal delivery of antigens (subunit or inactivated pathogens). This platform facilitates efficient passage through the mucosal barrier and significantly enhances immunogenicity and overall vaccine efficacy.

The company's expertise covers both veterinary and human vaccines targeting parasites, viruses, bacteria, and fungi.

Vaxinano is currently advancing a first-in-class Toxoplasma gondii vaccine into human clinical trials following extensive vaccination campaigns in non-human primates. The human health pipeline also includes vaccine candidates against bacterial, parasitic, and viral diseases, with promising results obtained in preclinical studies.

In the veterinary context, Vaxinano has licensed the first therapeutic vaccine against canine leishmaniasis**.** The veterinary pipeline is also composed of prophylactic vaccines against parasitic diseases (e.g., bovine neosporosis), against bacterial infections (avian colibacillosis, fish bacterial diseases), and a therapeutic vaccine against fungal infection (feline sporotrichosis).

Vaxinano is seeking collaborative partners to co-develop new prophylactic or therapeutic vaccines or to enhance existing formulations for both human and veterinary use. The nanoparticle platform supports mucosal administration of antigens derived from inactivated pathogens without the need for added adjuvants. The company has extensive experience in nanoparticle–antigen formulation, physicochemical characterization, and preclinical immunogenicity evaluation in mouse models, including both humoral and cellular immune responses. The company aims to join a consortium of scientific and industrial partners interested in evaluating intranasal and mucosal vaccine administration routes for human or veterinary applications, and we are particularly seeking partners with access to relevant animal challenge models.